Transvenous Approach for the Treatment of Cerebral Arteriovenous Malformations — TATAM  

Arteriovenous Malformations, Cerebral Clinical Trial

Official title: Transvenous Approach for the Treatment of Cerebral Arteriovenous Malformations (TATAM): A Randomized Controlled Trial and Registry

Status Active, not recruiting

Clinical Trial Summary

A new endovascular route for the treatment of brain AVMs may be possible in some cases: Trans-Venous Embolization (TVE). The technique uses microcatheters to navigate to the draining veins of AVM, to reach and then fill the AVM nidus retrogradely with liquid embolic agents until the lesion is occluded. This technique has the potential to improve on some of the problems with the arterial approach to AVM embolization, such as a low overall occlusion rate. However, by occluding the vein first, and filling the lesion with the embolic agent in a retrograde fashion, the method transgresses a widely held dogma in the surgical or endovascular treatment of AVMs: to preserve the draining vein until all afferent vessels have been occluded. Nevertheless, the initial case series have shown promising results, with high occlusion rates, and few technical complications. The method is increasingly used in an increasing number of centers, but there is currently no research protocol to guide the use of this promising but still experimental treatment in a prudent fashion. Care trials can be designed to offer such an experimental treatment, taking into account the best medical interests of patients, in the presence of rapidly evolving indications and techniques.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Arteriovenous Malformations
• Arteriovenous Malformations, Cerebral
• Congenital Abnormalities
• Hemangioma
• Intracranial Arteriovenous Malformations
• Ruptured Brain Arteriovenous Malformation
• Unruptured Brain Arteriovenous Malformation

• NCT number: NCT03691870
• Study type: Interventional
• Source: Centre hospitalier de l'Université de Montréal (CHUM)
• Status: Active, not recruiting
• Phase: N/A
• Start date: August 2, 2018
• Completion date: December 2025